The global PEGylated Proteins Market was valued at USD 690.54 million in 2016 and is projected to reach USD 1686.45 million by 2025, growing at a CAGR of 10.43% from 2017 to 2025.
PEGylation (often styled pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated (pegylated).
Sample Infographics:
Market Dynamics:
1. Market Drivers
1.1 Growing R&D Spending
1.2 Rising Biologics Sector
1.3 Technological developments in Protein Based Drugs and Non Protein Based drugs
1.4 Growing Protein's Stability
1.5 Major Lifestyle changes and associated diseases
2. Market Restraints
2.1 Drug Failure and Recalls Hinders Market Growth
Market Segmentation:
1. Global PEGylated Proteins Market, by End User:
1.1 Pharmaceutical & Biotechnology Companies
1.2 Contract Research Organization
1.3 Academic Research Institutes
2. Global PEGylated Proteins Market, by Application:
2.1 Cancer Treatment
2.2 HEPAtitis
2.3 Chronic Kidney Disease
2.4 Hemophilia
2.5 Multiple Sclerosis
2.6 Gastrointestinal Disorder
2.7 Other Application
3. Global PEGylated Proteins Market, by Protein Type:
3.1 Colongy Stimulating Factors
3.2 Interferons
3.3 Erythropoietin (EPO)
3.4 Recombinant Factor Viii
3.5 Monoclonal Antibodies
3.6 Other Protein Type
4. Global PEGylated Proteins Market, by Product:
4.1 Consumables
4.1.1 Pegylation Kits
4.1.2 Pegylation Reagents
4.1.2.1 Monofunctional Linear Pegs
4.1.2.2 Bifunctional Pegs
4.1.2.3 Multi-Arm Pegs
4.1.2.4 Branched Pegs
4.1.2.5 Other Pegylation Reagents
4.2 Services
4.2.1 Development of PEGylated Biosimilars
4.2.2 Process Development of Peg-Drug Conjugate Manufacturing
4.2.3 Pilot Production of Peg Drug Conjugate
4.2.4 Development of Analytical Methods
4.2.5 Pegylation Feasibility Studies
5. Global PEGylated Proteins Market, by Region:
5.1 North America (U.S., Canada, Mexico)
5.2 Europe (Germany, UK, France, Rest of Europe)
5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)
5.4 Latin America (Brazil, Argentina, Rest of Latin America)
5.5 Middle East & Africa
Competitive Landscape:
The major players in the market are as follows:
1. Merck Millipore
2. Thermo Fisher Scientific Inc.
3. NOF American Corporation (A Subsidiary of NOF Corporation)
4. Jenkem Technology
5. Creative Pegworks
6. Celares GmbH
7. Quanta Biodesign, Ltd
8. Biomatrik, Inc.
9. Iris Biotech GmbH
10. Laysan Bio, Inc.
These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.
RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:
Research study on the PEGylated ProteinsMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.
The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.
To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.
1 INTRODUCTION OF GLOBAL PEGYLATED PROTEINSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL PEGYLATED PROTEINSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL PEGYLATED PROTEINS MARKET, BY END USER
5.1 Pharmaceutical & Biotechnology Companies
5.2 Contract Research Organization
5.3 Academic Research Institutes
6 GLOBAL PEGYLATED PROTEINS MARKET, BY APPLICATION
6.1 Cancer Treatment
6.2 HEPAtitis
6.3 Chronic Kidney Disease
6.4 Hemophilia
6.5 Multiple Sclerosis
6.6 Gastrointestinal Disorder
6.7 Other Application
7 GLOBAL PEGYLATED PROTEINS MARKET, BY PROTEIN TYPE
7.1 Colongy Stimulating Factors
7.2 Interferons
7.3 Erythropoietin (EPO)
7.4 Recombinant Factor Viii
7.5 Monoclonal Antibodies
7.6 Other Protein Type
8 GLOBAL PEGYLATED PROTEINS MARKET, BY PRODUCT
8.1 Consumables
8.1.1 Pegylation Kits
8.1.2 Pegylation Reagents
8.1.2.1 Monofunctional Linear Pegs
8.1.2.2 Bifunctional Pegs
8.1.2.3 Multi-Arm Pegs
8.1.2.4 Branched Pegs
8.1.2.5 Other Pegylation Reagents
8.2 Services
8.2.1 Development of PEGylated Biosimilars
8.2.2 Process Development of Peg-Drug Conjugate Manufacturing
8.2.3 Pilot Production of Peg Drug Conjugate
8.2.4 Development of Analytical Methods
8.2.5 Pegylation Feasibility Studies
9 GLOBAL PEGYLATED PROTEINSMARKET, BY GEOGRAPHY
9.1 Overview
9.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
9.5.1 Brazil
9.5.2 Argentina
9.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025
10 GLOBAL PEGYLATED PROTEINSMARKETCOMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies
11 COMPANY PROFILES
11.1 Merck Millipore
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments
11.3 NOF American Corporation (A Subsidiary of NOF Corporation)
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments
11.4 Jenkem Technology
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments
11.5 Creative Pegworks
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments
11.6 Celares GmbH
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments
11.7 Quanta Biodesign, Ltd
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments
11.8 Biomatrik, Inc.
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments
11.9 Iris Biotech GmbH
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments
11.10 Laysan Bio, Inc.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments
12 Appendix
12.1 Related Reports
Asia Pacific bioprocess technology market will grow by 15.0% annually with a total addressable market cap of $170.71 billion over 2024-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
North America bioprocess technology market is projected to grow by 13.3% annually in the forecast period and reach $29.68 billion by 2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology s...
Global bioprocess technology market will reach $88.39 billion by 2033, growing by 13.8% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing technologic...
Overview of the Global Genetically Enhanced Bacterial Proteins Market:
The report discusses everything a marketer requires before investing in the global Genetically Enhanced Bacterial Proteins Market during the for...
Overview of the Global Biotechnologically Altered Bacterial Proteins Market:
The report discusses everything a marketer requires before investing in the global Biotechnologically Altered Bacterial Proteins Market du...
Overview of the Global Modified Genetically Engineered Bacterial Proteins Market:
The report discusses everything a marketer requires before investing in the global Modified Genetically Engineered Bacterial Proteins...
Overview of the Global Genetically Modified Bacterial Proteins Market:
The report discusses everything a marketer requires before investing in the global Genetically Modified Bacterial Proteins Market during the for...
The global Recombinant Human Proteins market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players i...
The global Recombinant Non-Glycosylated Proteins Biosimilars market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which wil...